Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP lessened its stake in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 22.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 260,300 shares of the company's stock after selling 76,000 shares during the quarter. Two Sigma Advisers LP owned about 0.40% of Kymera Therapeutics worth $10,472,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Blue Trust Inc. raised its position in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. State of Wyoming purchased a new stake in Kymera Therapeutics in the 4th quarter valued at $45,000. KBC Group NV raised its position in Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Kymera Therapeutics by 95.5% in the 4th quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock valued at $194,000 after purchasing an additional 2,350 shares during the last quarter. Finally, Summit Investment Advisors Inc. raised its position in Kymera Therapeutics by 9.0% in the 4th quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock valued at $198,000 after purchasing an additional 406 shares during the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In other news, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $30.45, for a total transaction of $214,215.75. Following the completion of the sale, the chief financial officer now owns 201,886 shares of the company's stock, valued at approximately $6,147,428.70. This trade represents a 3.37% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now directly owns 67,800 shares of the company's stock, valued at $2,064,510. The trade was a 2.00% decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,659 shares of company stock valued at $324,567 over the last 90 days. 16.01% of the stock is owned by corporate insiders.

Kymera Therapeutics Stock Performance

KYMR traded up $1.46 on Wednesday, reaching $29.60. 508,256 shares of the company's stock were exchanged, compared to its average volume of 562,365. The company's 50 day moving average is $28.78 and its 200-day moving average is $36.09. The company has a market cap of $1.93 billion, a price-to-earnings ratio of -12.65 and a beta of 2.18. Kymera Therapeutics, Inc. has a twelve month low of $19.45 and a twelve month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings data on Friday, May 9th. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $22.10 million during the quarter, compared to the consensus estimate of $11.38 million. During the same quarter last year, the company earned ($0.69) earnings per share. Kymera Therapeutics's revenue for the quarter was up 114.6% on a year-over-year basis. Sell-side analysts forecast that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Wall Street Analysts Forecast Growth

KYMR has been the topic of several recent research reports. UBS Group dropped their price objective on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Stifel Nicolaus initiated coverage on shares of Kymera Therapeutics in a research note on Tuesday, May 20th. They issued a "buy" rating and a $55.00 price objective on the stock. Wall Street Zen raised shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Bank of America dropped their price objective on shares of Kymera Therapeutics from $47.00 to $44.00 and set a "neutral" rating on the stock in a research note on Monday, May 12th. Finally, HC Wainwright boosted their price objective on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Five equities research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $55.25.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.